View clinical trials related to Metabolic Diseases.
Filter by:The aim of this research study is to determine by laboratory analyses the effects of drinking silicon-rich water on bone health. This will be determined from blood and urine samples from subjects who will be asked to drink 1 liter per day of either silicon-rich water or water without silicon for 12 weeks.
Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders. Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule). The primary objective of the study is to investigate mean changes in Hepatic Triglyceride Content (HTGC), which is the fat content of the liver, from baseline to week 6 and 12 by 1H-Magnetic Resonance Spectroscopy (MRS), a specialized non invasive radiology test. Additional measures include body mass index (BMI), fasting glucose,lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.
The purpose of this study is to determine safety and efficacy of mipomersen (ISIS 301012) in the reduction of total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in high risk subjects intolerant to statins.
To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849), 301012-CS17 (NCT00477594) or MIPO3500108 (NCT00794664) clinical drug trials.
Eleven National Sports Teams are located in the Quebec Metropolitan Area. In these groups, many athletes are aiming for Olympic medals in Beijing 2008 and Vancouver 2010 Olympic Games. A consultation of the coaches of these National Teams revealed that although a large proportion of these athletes present various cardio-respiratory symptoms, they do not have a rapid access to a systematic medical evaluation and follow-up. Furthermore, little is done in regard to prevention and optimization of treatment of pulmonary and cardiac conditions in the elite athlete's population of the Quebec area. Cardiorespiratory problems are therefore commonly found in high-level athletes. However, these pathologies are not well characterized in athletes and the associated symptoms often not well perceived. These problems can be serious and it is important to detect them before they appear1 while setting up a systematic medical follow-up. Health professionals should monitor health of the young athletes and help to reduce the risks associated with high level exercise. The following project is an evaluation and follow-up program of high-level athletes, aiming at gathering key-information on long-term effects of high-level training on cardio-respiratory and metabolic parameters. Our aims will be 1. to establish a long-term program of systematic evaluation and follow-up of cardiorespiratory health and performance of high elite athletes. 2. to evaluate the prevalence of respiratory, circulatory and metabolic problems among high-level athletes 3. to evaluate the effects of treatments on cardiorespiratory conditions and exercise performance in athletes who need asthma medication.
This research had as a goal to characterize the social demographic profile, nutritional status, the presence of chronic non-transmissible diseases and food intake of the community health agents who belong to five family health units in the east zone of Sao Paulo City.
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin. The primary measure of effectiveness is the change in concentration of glycated hemoglobin (HbA1c) during treatment. Glycated hemoglobin is a substance in red blood cells that is formed when blood sugar (glucose) attaches to hemoglobin and is a measure of diabetic status. Additional measures include fasting glucose, and lipid levels, and body weight. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.
The aims of this study are to prospectively evaluate the efficacy of two intravenous infusions of pamidronate 90 mg, associated with calcium and calcidiol, in the early post-transplant period, on bone loss in liver transplant recipients, and to asses the safety of this treatment.
Gather additional efficacy and safety (pharmacovigilance) information in the usual daily care in patients with Dyslipidemia on ezetimibe under real conditions in Colombia associated with statins.